Low-Dose Atorvastatin Enhances Outcomes in Clinically Significant Macular Edema: Study

A new clinical study published in the Romanian Journal of Ophthalmology revealed that low-dose atorvastatin (10–20 mg) used along with anti-vascular endothelial growth factor (VEGF) therapy showed better functional and anatomical outcomes in diabetic patients with clinically significant macular edema (CSME) when compared to high-dose therapy. The findings of the study suggest that there were added benefits of lower statin dosing in management in patients suffering from non-proliferative diabetic retinopathy (NPDR) and clinically significant macular edema (CSME).

This prospective, randomized study evaluated type 2 diabetic patients based on their statin dosage, where one group received low-dose atorvastatin (10–20 mg), and the other group received a higher dose (30–40 mg). All participants underwent standard treatment with intravitreal ranibizumab injections, which was given in 3 initial monthly doses followed by additional treatments as needed over 6 months.

At the end of the study period, both groups required a similar number of anti-VEGF injections, which averaged to 3.4 injections overall. However, the key differences emerged in visual and anatomical outcomes. The patients receiving the lower statin dose experienced more consistent and sustained improvements in best-corrected visual acuity (BCVA) at both 3 and 6 months. The results also showed a marked reduction in central macular thickness (CMT) which indicates retinal swelling.

In contrast, while the high-dose group showed some early improvement in vision at the 3-month mark, these gains were not maintained at six months. Their reduction in macular thickness was also less consistent over time, which suggested a diminished long-term benefit. Also, the patients in the low-dose group showed a reduction in the serum VEGF levels over 6 months, whereas those in the high-dose group experienced an increase.

The improved outcomes in the low-dose group may be linked to the broader biological effects of statins beyond cholesterol reduction. These pleiotropic effects include anti-inflammatory and anti-angiogenic properties, which may help in stabilizing retinal tissue and reducing fluid leakage. Despite similar treatment intensity in terms of injections, the superior response observed in the low-dose group suggests that more is not always better when it comes to statin therapy.

Overall, the findings of this study suggest that low-dose atorvastatin may serve as a valuable adjunct to anti-VEGF therapy in managing diabetic macular edema, potentially offering patients a more effective and sustained improvement in vision. Further investigation into how statin dosing influences retinal health and whether personalized dosing strategies could improve patient outcomes are required.

Source:

Markan, A., Agarwal, A., Katoch, D., Bhadada, S., Gupta, V., & Bansal, R. (2025). Assessing the role of statins as an adjunctive anti-VEGF therapy for clinically significant macular edema (CSME) in type 2 diabetes mellitus. Romanian Journal of Ophthalmology, 69(2), 219–227. https://doi.org/10.22336/rjo.2025.35